Management Guidelines for Eosinophilia (Cited Evidence)

Therapeutic Strategies by Etiology

Empirical albendazole 400 mg twice daily for 7 days is highly effective for unexplained eosinophilia in endemic regions, while corticosteroids remain the first‑line therapy for hypereosinophilic syndrome (HES) and lymphocyte‑variant hypereosinophilia, and imatinib is the definitive treatment for PDGFRA/PDGFRB‑rearranged disease. 1
In schistosomiasis‑related eosinophilia (Katayama syndrome), species‑specific praziquantel is the treatment of choice; acute presentations may require supportive care during the immune‑response phase. 1

Diethylcarbamazine (DEC) must not be administered to patients with a high microfilarial load (≈ > 1 000 microfilariae/mL) because it can precipitate fatal encephalopathy; instead, a short course of corticosteroids combined with albendazole should be used first to lower the microfilarial burden before DEC therapy. 1
Travelers from Loa loa‑endemic areas should have microfilaraemia assessed before any empirical DEC use, as encephalopathy carries a high mortality risk. 1

Secondary causes (e.g., drug‑induced eosinophilia, atopic disease—accounting for roughly half of identifiable cases) must be excluded before initiating disease‑directed therapy. 1
Prompt molecular/cytogenetic testing for PDGFRA and PDGFRB rearrangements is essential in persistent unexplained hypereosinophilia, because failure to identify these alterations deprives patients of highly effective imatinib therapy. 1

Serologic testing is unreliable for confirming cure of schistosomiasis, as antibodies may remain positive for years; follow‑up should rely on repeat stool microscopy (despite low sensitivity) or clinical/imaging assessment (e.g., ultrasound for hepatosplenic disease). 1
In HES patients receiving corticosteroids or targeted agents, regular monitoring of eosinophil counts and end‑organ function (cardiac echocardiography, pulmonary function testing, neurologic examination) is required to gauge response and prevent irreversible damage. 1